Skip to main content
NewslettersWatchlist

Cipher Pharmaceuticals Inc(CPH-T)
TSX

Today's Change
Real-Time Last Update
Day Low14.29
Day High14.74
Open:14.74
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
PR Newswire
Cipher Pharmaceuticals Reports Third Quarter 2024 Results
Newswire.ca
Cipher Pharmaceuticals Schedules Q3 2024 Earnings Release and Conference Call
PR Newswire
Cipher Pharmaceuticals Schedules Q3 2024 Earnings Release and Conference Call
AI-generated - The Globe and Mail
Cipher Pharmaceuticals: Stocks Overvalued by Analyst Consensus on TSX (CPH)
Baystreet
Stocks in play: Cipher Pharmaceuticals Inc.
Newswire.ca
Cipher Pharmaceuticals Enhances Leadership Team with Appointment of New Chief Business Officer
PR Newswire
Cipher Pharmaceuticals Enhances Leadership Team with Appointment of New Chief Business Officer
AI-generated - The Globe and Mail
Cipher Pharmaceuticals: Stocks Overvalued by Analyst Consensus on TSX (CPH)
Newswire.ca
Cipher Pharmaceuticals Partner Moberg Pharma AB Provides Update on MOB-015 Phase 3 Study
AI-generated - The Globe and Mail
Cipher Pharmaceuticals: Top 25 Performing Stocks Year-to-Date on Toronto Stock Exchange (CPH)
Newswire.ca
Cipher Pharmaceuticals Reports Second Quarter 2024 Results
Newswire.ca
Cipher Pharmaceuticals Schedules Q2 2024 Earnings Release and Conference Call
Baystreet
Stocks in play: Cipher Pharmaceuticals Inc.
Newswire.ca
Cipher Pharmaceuticals Acquires Profitable Growth Dermatology Products from ParaPRO for US$89.5 Million
Newswire.ca
Cipher Pharmaceuticals Announces Results of Annual and Special Meeting of Shareholders
Newswire.ca
Cipher Pharmaceuticals Reports First Quarter 2024 Results
Baystreet
Stocks in play: Cipher Pharmaceuticals Inc.
Newswire.ca
Cipher Pharmaceuticals Schedules Q1 2024 Earnings Release and Conference Call
AI-generated - The Globe and Mail
Cipher Pharmaceuticals: Stocks Overvalued by Analyst Consensus on TSX (CPH)
Baystreet
Stocks in play: Cipher Pharmaceuticals
Newsfile
Cipher Pharmaceuticals Announces Participation in the 2024 Bloom Burton & Co. Healthcare Investor Conference
AI-generated - The Globe and Mail
Cipher Pharmaceuticals: Stocks Overvalued by Analyst Consensus on TSX (CPH)

Profile

Cipher Pharmaceuticals Inc is a specialty pharmaceutical company. Its products include Dermatology Products, Hospital Acute Care Products, specialty medicines, and Out-Licensed Products among others. The company's geographical operational areas include Canada and the United States.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright ยฉ 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright ยฉ 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.